GB2607402.1 — Osseous Regeneration Scaffold
Bone that rebuilds itself. Grown from seaweed. No donor site. No growth factor injections. Works in a field hospital. A sargassum-derived scaffold with intrinsic osteoinductive activity — fucoidan drives mesenchymal stem cells to become bone-forming cells without rhBMP, without a cold chain, and without the oncogenic risk that has shadowed recombinant growth factor therapy for two decades.
Critical-size bone defects from blast injury, resection, and osteomyelitis currently have three treatment options. Every one of them has a structural failure mode that RAPIDBone eliminates.
Current gold standard
Patient's own bone harvested from iliac crest or fibula. Best biological integration. No immunogenic risk.
Supply-limited — you can only harvest so much bone from one patient
Donor site morbidity — second surgical wound, chronic pain, infection risk at harvest site
Impossible in major blast trauma — insufficient viable bone available to harvest
Not deployable in field hospital or resource-limited setting
Donor bone — bank dependent
No donor site morbidity. Available in larger volumes. Reasonable integration outcomes.
Bone bank supply chain — unavailable forward deployed, unavailable in resource-limited settings
Disease transmission risk — despite screening, residual pathogen transmission risk remains
Immunogenic mismatch potential — rejection and inflammatory response possible
No intrinsic osteoinductive activity — passive scaffold only
Recombinant growth factor
Osteoinductive — drives bone formation without donor material. Proven clinical use in spinal fusion.
Oncogenic risk — FDA black box warning for cervical spine; off-label use linked to ectopic bone, cancer risk
Expensive — $5,000–$15,000 per application in the US market
Cold chain dependent — protein stability requires refrigeration throughout supply chain
Supraphysiological doses required — the therapeutic dose is orders of magnitude above natural concentrations
RAPIDBone's osteoinductive activity depends entirely on a single upstream decision — non-thermal processing of the sargassum feedstock. Everything else follows from that.
Fucoidan's osteoinductive properties are well documented in the literature. What is not documented is a fucoidan source that retains the native sulphation pattern required to deliver those properties at physiological dose from a manufacturable scaffold. Non-thermal processing of Bio-Farm sargassum is that source. No prior art describes it. RAPIDBone — GB2607402.1 — inventive step summary
The critical distinction is not fucoidan — it is native sulphation. Commercial fucoidan is thermally extracted. Thermal processing destroys the sulphation pattern. The sulphation pattern is what drives MSC differentiation toward the osteogenic lineage. Without native sulphation, you have fucoidan in name only.
Non-thermal sargassum harvest
Bio-Farm controlled grow-out followed by proprietary non-thermal extraction — preserves native fucoidan sulphation pattern intact. No prior art describes this protocol for pelagic sargassum.
Nano-hydroxyapatite composite
Native-sulphation fucoidan combined with nano-hydroxyapatite — the mineral phase of bone. Scaffold architecture mimics natural bone extracellular matrix at the nanoscale. In vivo biomineralisation proceeds without exogenous stimulation.
Intrinsic MSC osteoinduction
Native fucoidan sulphation drives mesenchymal stem cell differentiation toward the osteogenic lineage. No rhBMP required. No supraphysiological dosing. No oncogenic risk. Patient's own MSCs respond to the scaffold.
CT-derived patient geometry
Scaffold fabricated to patient-specific geometry from CT imaging data. Critical for load-bearing applications — geometry determines mechanical performance. Off-the-shelf scaffolds cannot achieve this.
RAPIDBone delivers osteoinduction, antimicrobial protection, vascularisation, and structural mineralisation from the same scaffold — addressing the four concurrent requirements of critical-size bone defect repair.
Fucoidan — MSC → osteoblast differentiation
Native-sulphation fucoidan drives mesenchymal stem cell differentiation along the osteogenic lineage — osteoblast formation, collagen matrix deposition, and mineralisation. Intrinsic. No exogenous growth factors. Physiological dose. No FDA black box. No oncogenic mechanism.
Advantage over rhBMP: same outcome, zero oncogenic risk, ambient stable, fraction of the cost
nano-HA composite — structural mineralisation
The nano-hydroxyapatite phase provides an immediate mineral template. As osteoblasts differentiate and deposit collagen matrix, the scaffold undergoes progressive biomineralisation — transitioning from synthetic scaffold to living bone over the healing timeline. The scaffold architecture degrades as the patient's own bone replaces it.
No staged procedures — one scaffold, complete mineralisation during healing
Phlorotannins + holobiont — non-antibiotic antimicrobial
Osteomyelitis — bone infection — is the primary complication of open fractures and blast bone injuries. Phlorotannins prevent biofilm formation. Holobiont antimicrobials deliver MRSA-active non-antibiotic activity. Infection prevention is built into the scaffold — not administered separately and not dependent on systemic antibiotics.
Critical for blast bone injuries where contamination is universal
Fucoidan — Akt/Nrf2/HIF-1α angiogenesis
Bone regeneration requires vascular ingrowth — without blood supply, the scaffold cannot support active mineralisation. Fucoidan promotes angiogenesis via the Akt/Nrf2/HIF-1α pathway, establishing the vascular network required for osteoblast survival and bone matrix deposition throughout the scaffold volume.
Intrinsic — same fucoidan that drives osteoinduction also drives vascularisation
RAPIDBone addresses the bone defect categories where autograft supply fails, allograft is unavailable, and rhBMP carries unacceptable risk. Combat is the primary validation. Civilian orthopaedics and maxillofacial surgery follow the same mechanism.
Combat — primary indication
IED injuries create critical-size bone loss in femur, tibia, and pelvis where autograft supply is exhausted and allograft is unavailable forward deployed. CT-derived geometry enables patient-specific reconstruction. Non-antibiotic osteomyelitis protection addresses universal blast wound contamination.
Previous standard: Staged autograft — multiple surgeries, donor site morbidity, incomplete reconstruction
Combat + civilian — orthopaedics
Infected bone must be resected, leaving a critical-size defect that cannot be immediately reconstructed with donor material. RAPIDBone's intrinsic antimicrobial activity addresses residual contamination while osteoinduction drives reconstruction — one scaffold, two problems simultaneously.
Previous standard: Antibiotic cement spacer followed by delayed reconstruction — multiple procedures, extended timeline
Civilian — orthopaedic oncology
Bone tumour resection creates planned critical-size defects. rhBMP is contraindicated where oncogenic risk is already present. RAPIDBone's intrinsic osteoinduction without growth factors eliminates this contraindication. CT geometry enables precise reconstruction of resection margins.
Previous standard: Allograft or prosthetic reconstruction — no osteoinductive activity, mechanical failure over time
Civilian — spine surgery
rhBMP is widely used in spinal fusion but carries an FDA black box warning for cervical applications and documented off-label oncogenic risk. RAPIDBone provides the same osteoinductive outcome with zero oncogenic mechanism — a direct drop-in replacement for rhBMP in fusion applications.
Previous standard: rhBMP at $5k–$15k per application with black box oncogenic risk
Civilian — craniofacial surgery
Blast and trauma injuries to the craniofacial skeleton require complex geometry reconstruction. CT-derived patient-specific fabrication enables precise craniofacial scaffold geometry impossible with off-the-shelf products. Osteomyelitis protection is critical in the contamination-prone craniofacial region.
Previous standard: Custom titanium plates or allograft — no osteoinductive activity, infection risk
Civilian — trauma orthopaedics
Fractures that fail to heal — non-unions — represent a significant clinical and economic burden. The osteoinductive activity of native fucoidan stimulates the stalled healing response without the risks of exogenous growth factor therapy. Applicable in resource-limited settings where cold chain for rhBMP is unavailable.
Previous standard: Bone marrow aspirate, electrical stimulation, revision autograft — variable outcomes
Direct comparison across the five parameters that define clinical utility in critical-size bone defect repair.
| Parameter | Autograft | rhBMP | RAPIDBone |
|---|---|---|---|
| Osteoinductive | Yes | Yes | Yes — intrinsic fucoidan |
| Donor site morbidity | Yes — second wound | None | None |
| Oncogenic risk | None | Yes — FDA black box | None — no growth factor mechanism |
| Cold chain required | No | Yes — protein stability | No — ambient stable |
| Supply limitation | Yes — patient anatomy | None | None — Bio-Farm feedstock |
| Antimicrobial | None | None | Intrinsic — MRSA active, non-antibiotic |
| Patient-specific geometry | Limited | No | Yes — CT-derived fabrication |
| Feedstock cost | Surgical time | $5,000–15,000 (US) | £0 — Bio-Farm sargassum |
| Forward deployable | No — OR dependent | No — cold chain | Yes — ambient stable |
| Parameter | Specification |
|---|---|
| Scaffold base | Arsenic-remediated pelagic sargassum, non-thermal processing |
| Mineral phase | Nano-hydroxyapatite (nano-HA) composite |
| Osteoinduction | Intrinsic — native-sulphation fucoidan, no rhBMP |
| Geometry | Patient-specific fabrication from CT imaging data |
| Cold chain | Not required — ambient stable |
| Antimicrobial | MRSA-active, non-antibiotic — phlorotannins + holobiont |
| Donor material | None — non-human origin, zero immunogenic risk |
| Degradation | Progressive — scaffold replaced by patient's own bone |
| Arsenic compliance | ICH Q3D pharmaceutical grade |
| Regulatory pathway | Class III Medical Device (EU MDR) / PMA (FDA) |
| Current TRL | 3 — patent filed, pre-clinical development |
Intellectual property
GB2607402.1
RAPIDBone — Osseous Regeneration Scaffold from Non-Thermally-Processed Pelagic Sargassum with Nano-Hydroxyapatite Composite
Sargassum-derived scaffold with nano-HA composite retaining native fucoidan sulphation via non-thermal processing — enabling intrinsic osteoinduction without exogenous growth factors
Non-thermal extraction protocol as the inventive step — distinguishes RAPIDBone from all prior art fucoidan scaffold products which use thermally extracted fucoidan
Methods of use — critical-size bone defect repair, osteomyelitis, spinal fusion, maxillofacial reconstruction, non-union fracture treatment
CT-derived patient-specific geometry fabrication method for load-bearing and craniofacial applications
Pharmaceutical-grade sargassum supply chain — arsenic management protocol achieving ICH Q3D inorganic limits as a function of extraction selectivity
Osseous reconstruction
RAPIDBone
You are here
Orthopaedic surgery · Defence procurement · Oncology · Spine surgery
Full technical documentation, patent application GB2607402.1, pre-clinical evidence base, and comparative analysis against autograft and rhBMP available under NDA to qualified partners.